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SUMMARY
The recent finding that reprogrammed human plurip-
otent stem cells can be derived by nuclear transfer
into human oocytes aswell as by induced expression
of defined factors has revitalized the debate on
whether one approach might be advantageous over
the other. Here we compare the genetic and epige-
netic integrity of human nuclear-transfer embryonic
stem cell (NT-ESC) lines and isogenic induced plurip-
otent stem cell (iPSC) lines, derived from the same
somatic cell cultures of fetal, neonatal, and adult
origin. The two cell types showed similar genome-
wide gene expression and DNA methylation profiles.
Importantly, NT-ESCs and iPSCs had comparable
numbers of de novo coding mutations, but signifi-
cantly more than parthenogenetic ESCs. As iPSCs,
NT-ESCs displayed clone- and gene-specific aberra-
tions in DNA methylation and allele-specific expres-
sion of imprinted genes. The occurrence of these
genetic and epigenetic defects in both NT-ESCs
and iPSCs suggests that they are inherent to reprog-
ramming, regardless of derivation approach.
INTRODUCTION
Cellular reprogramming to pluripotency is a remarkable process
by which somatic cells become embryonic-like stem cells,
capableof self-renewal anddifferentiation intoall threeembryonic
germ layers. Reprogramming can be induced in somatic cells by
enforced expression of transcription factors, resulting in induced
pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006).
Alternatively, transfer of somatic nuclei into oocytes can lead to
acquisition of pluripotency in a process knownas somatic cell nu-
clear transfer (SCNT). In initial studies on SCNT with human oo-
cytes, development to the blastocyst stage required the retention
of the oocyte genome, resulting in triploid nuclear-transfer embry-
onic stem cells (NT-ESCs) (Noggle et al., 2011).More recently, we
and others have succeeded in deriving diploid human NT-ESC
lines from fetal, infant, or adult fibroblasts (Chung et al., 2014; Ta-
chibanaet al., 2013;Yamadaet al., 2014). UponSCNT, the oocyte
elicits a dramatic reprogramming process that resets the epige-
nomeof the somaticnucleus toanearly embryonicstate.Thispro-
cess entails vast changes in chromatin and genome-wide DNA
demethylation, recapitulatingevents thatoccuruponnormal fertil-
ization (Chan et al., 2012). In contrast, iPSC generation involves
the targetedmanipulationof geneexpression, raising thequestion
of whether differences in the mechanisms of reprogramming are
also reflected in the resulting cells.
Studies in human pluripotent stem cells have pointed to ge-
netic and epigenetic alterations during reprogramming that
distinguish iPSCs from blastocyst-derived ESCs. These differ-
ences include alterations related to DNA methylation (Lister
et al., 2011; Ruiz et al., 2012) and hydroxymethylation (Wang
et al., 2013), memory of tissue origin (Bar-Nur et al., 2011;
Ohi et al., 2011), disease modeling (Urbach et al., 2010), and
regulation of imprinted genes (Pick et al., 2009). As these studies
compared genetically heterogeneous sources of cell lines, the
extent to which the somatic cell origin or the specific method
used to generate pluripotent stem cells contribute to these differ-
ences has remained unclear. More recently, differences in gene
expression and DNA methylation between NT-ESCs and
isogenic iPSCs derived from fetal fibroblasts have suggested
that reprogramming by SCNT is more efficient at removing
somatic cell features (Ma et al., 2014).
Human iPSCs can harbor various forms of genomic aberra-
tions, such as gain or loss of chromosomal or subchromosomal
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regions (Mayshar et al., 2010). Importantly, human iPSCs were
also shown to acquire de novo coding mutations throughout
their genome (Gore et al., 2011; Ji et al., 2012). The lengthy dura-
tion and number of cell cycles associated with reprogramming
by defined factors have been proposed as causes for the accu-
mulation of mutations in iPSCs. Nonetheless, it is unclear
whether reprogramming through SCNT, which occurs in a
shorter time window than reprogramming to iPSCs (Egli et al.,
2011), may differ in mutational load.
Another major aspect of cellular reprogramming concerns the
stability of epigenetic information. One of the well-studied epige-
neticphenomena influencingmammaliandevelopment isparental
genomic imprinting. Genomic imprints are marks of DNA methyl-
ation that differentiate the maternal and paternal genomes and
underlie the parent-of-origin differential regulation of imprinted
genes. Exclusively established in the germline in a sex-specific
manner, parental imprints cannot be restored in other lineages
once lost. Therefore, whereas the majority of methylated sites in
the genome undergo demethylation in the preimplantation em-
bryo, imprinted loci are protected from demethylation to maintain
differential methylation throughout embryogenesis and adult life
(Li et al., 2008; Messerschmidt et al., 2012). The imprinting status
of human ESCs is generally stable, yet gene-specific variability
has been reported in association with prolonged culturing
(Adewumi et al., 2007; Frost et al., 2011; Kim et al., 2007; Rugg-
Gunn et al., 2007). Human iPSCs feature a potentially higher de-
gree of imprint instability, which may arise either in their somatic
progenitors or during reprogramming and culturing (Nazor et al.,
2012; Nishino et al., 2011; Pick et al., 2009). Whether human
SCNT affects the integrity of genomic imprints is unknown.
Considering the unpredictable outcomes of coding mutations
on cellular function, as well as the diverse developmental roles
and tumorigenic potential of imprinted genes (Jelinic and
Shaw, 2007), both genetic stability and epigenetic stability are
relevant to the functionality and safety of reprogrammed human
pluripotent stem cells. Here we determined the prevalence of
coding mutations and aberrations in genomic imprinting in
isogenic human NT-ESCs and iPSCs derived from the same
somatic cell cultures. Using whole-exome sequencing analysis
along with gene expression and DNA methylation profiling, we
find that irrespective of the reprogramming method used, both
human NT-ESCs and iPSCs display comparable incidence of
de novo coding mutations and imprinting aberrations, demon-
strating that genetic as well as epigenetic defects are inherent
to reprogramming of human somatic cells to pluripotency.
RESULTS
Generation and Characterization of Isogenic Human
NT-ESCs and iPSCs
To study the consequences of reprogramming human somatic
cells by either SCNT or defined factors, we sought to overcome
the effects of genetic heterogeneity by generating two sets of
isogenic cell lines, derived from neonatal foreskin fibroblasts
(BJ) and adult dermal fibroblasts of a type 1 diabetic subject
(ID 1018), and comprising a total of four NT-ESC lines (Yamada
et al., 2014) and five iPSC lines (Figure 1A, Table S1 available
online). iPSCs were reprogrammed from the same somatic cell
cultures used for SCNT using modified RNAs (Figures S1A and
S1B available online). Global transcriptional characterization by
RNA sequencing (RNA-Seq) analysis indicated that both NT-
ESCs and iPSCs cluster together with ESC line NYSCF1 (Noggle
et al., 2011) and segregate away from their somatic cells of origin
(Figure 1B). Although most cell lines clustered by genetic back-
ground and derivation technique, the cosegregation of an NT-
ESC line (1018-NT-ES) and its isogenic iPSC counterparts with
genetically distinct iPSC lines (BJ-iPS-M and O) and NYSCF1
shows that both reprogramming processes result in highly
similar pluripotent cellular states (Figure 1B). Differential gene
expression analysis comparing NT-ESCs and iPSCs (false dis-
covery rate [FDR] < 0.05) demonstrated negligible differences
in only 6 genes. Inspecting the expression levels of these genes
in AmaZonia! showed that they are variably expressed in both
ESCs and iPSCs, and none of them displays meaningful differ-
ences. This is consistent with the clustering analysis in Figure 1B
and with the homogeneous upregulation of pluripotency genes
and silencing of fibroblast-specific genes (Figure 1C), demon-
strating effective reprogramming by either method.
Human NT-ESCs and iPSCs Show Comparable Rates of
De Novo Coding Mutations
To determine the number of de novo coding mutations, we per-
formed whole-exome sequencing on the four NT-ESC lines, their
cognate iPSC lines, and the two parental fibroblast cultures. We
also sequenced three NT-ESC lines, two isogenic iPSC lines,
and parental fibroblasts of fetal origin (Ma et al., 2014; Tachi-
bana et al., 2013; Yamada et al., 2014). Hybridization-based
exome sequencing was used to characterize protein-coding re-
gions and mutation calls were verified with Sanger sequencing.
Of the 20,464 known single nucleotide polymorphisms (SNPs)
that were identified in consensus coding sequence (CCDS) re-
gions of each fibroblast sample, 96%–99% were also called in
the stem cell lines, indicating a false negative rate of <5% (Table
S2). Overall, the average number of unique de novo point muta-
tions was 10.57 for the seven NT-ESC lines and 10.43 for the
seven isogenic iPSC lines (Figures 2A and 2B). The number of
observed mutations between each pluripotent stem cell type
was statistically indistinguishable by a Mann-Whitney rank
sum test (p = 0.64), indicating that the reprogramming method
does not play a strong role in the acquisition of de novo point
mutations. Of those, an average of 8.00 ± 1.8 and 7.43 ± 0.8 mu-
tations, respectively, were nonsynonymous. Sanger sequencing
further revealed that in an average of 1.2 of all mutations, the
mutated peak was at least 50% smaller than the wild-type
peak (Figure 2C). A possible explanation is that these mutations
occurred in the postreprogramming culture and therefore were
carried by only some of the cells that were sequenced. Notably,
the number of confirmed mutations varied widely between
clones derived from the three somatic cell sources (Figure 2A).
Most mutations were found in NT-ESCs and iPSCs of adult so-
matic cell origin, 14 of which were shared between all three
iPSCs. This observation suggests that these mutations preex-
isted in a significant population of parental somatic cells,
because mutations shared between independent reprogram-
ming events cannot be the result of the reprogramming process
(Figure 2A). What further set the 1018 lines apart was the pres-
ence of dinucleotide variations: 28% of the 1018-NT-ES muta-
tions and 42% of the mutations in 1018-iPS-A, B, and C were
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dinucleotide mutations (Figures 2A and 2D). Functional annota-
tion analysis by DAVID did not reveal any significant pathway
enrichment among the mutated genes, and none of the nonsy-
nonymous mutations occurred in genes that are predicted to
provide a growth advantage.
In addition, we sequenced the exomes of five NT-ESC lines
containing both somatic and oocyte genomes (soPSCs; Fig-
ure S1) (Noggle et al., 2011) and found an average of 6.8 ± 2.4
mutations (Table S3). We also sequenced two retrovirally reprog-
rammed iPSC lines that were derived from the same somatic cell
lines and found eight and nine mutations. Because of the differ-
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Figure 1. Generation and Characterization
of Isogenic Human NT-ESCs and iPSCs
(A) Experimental scheme illustrating the derivation
of isogenic human pluripotent stem cell lines from
two somatic cell sources and control ESCs derived
from an in vitro fertilized blastocyst.
(B) Hierarchical clustering analysis of the isogenic
sets of NT-ESCs, iPSCs, parental fibroblasts,
and control ESC line NYSCF1, based on auto-
somal transcriptional signatures as determined by
RNA-Seq analysis (Pearson correlation, average
linkage).
(C) Expression levels of pluripotency-specific
genes (upper inset) and fibroblast-specific genes
(lower inset) based on RNA-Seq data (FPKM
ratios).
ence in ploidy between soPSCs and
iPSCs, these mutation rates cannot be
directly compared, because decreased
representation of a single mutation in
soPSCs would decrease the call rate. By
using allele-specific primers for mutations
and flanking SNPs that distinguished be-
tween the somatic cell and oocyte donors
in one of the triploid NT-ESC line (soPS1),
we confirmed that all tested mutations
(seven of seven) localized to the somatic
genome. This result is very unlikely ifmuta-
tions arose during postreprogramming
culture, because in this case, mutations
would be spread across both donor ge-
nomes. We can thus conclude that de
novo mutations occur specifically in the
somatic cell genome prior to or during
reprogramming.
To further analyze the number of muta-
tions expected to occur as a result of stem
cell culture, we sequenced the exomes
of four parthenogenetic ESC (pESC) lines
(Paull et al., 2013). pESC lines are diploid
homozygotes as a result of polar body
extrusion and endoreduplication during
preimplantation development. Because
of this unique genetic property, pre-
existing heterozygous donor mutations
generated during germline development
become homozygous. In contrast, muta-
tions arising during in vitro culture would be heterozygous or
mosaic. Thus, preexisting rare mutations can be distinguished
from newly occurring mutations. Furthermore, pESCs differ
fromNT-ESCsonly in the sourceof the genome,while other steps
of their derivation, including artificial activation of unfertilized oo-
cytes, culture, and derivation are identical. Therefore, pESCs are
an ideal control for the frequency of de novo mutations arising
due to mechanisms unrelated to somatic cell reprogramming.
While we found a total of 23 homozygous mutations in the four
pESCs (Figure 2B; Table S3), an average of only 1.25 heterozy-
gous mutations were found per pESC line, a significantly lower
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number (p = 0.0007) than that found in our reprogrammed stem
cell lines. Thus, on average, irrespective of the reprogramming
approach, an average of 9.25 (10.5 – 1.25) mutations in iPSCs
and NT-ESCs are the consequence of de novo mutations occur-
ring during reprogramming or are preexisting mutations inherited
from parental somatic cells.
Clone- and Gene-Specific Loss of Imprinting in Human
NT-ESCs and iPSCs
To delineate the epigenetic integrity of human NT-ESCs, we
initially examined the transcriptional status of imprinted genes
in various human pluripotent stem cells, including several sam-
ples of ESCs, iPSCs, and NT-ESCs, by microarray analysis. As
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Figure 2. Coding Mutations in Human NT-ESCs and iPSCs
(A) List of mutations in NT-ESCs and iPSC lines. (*), 14 mutations shared between 1018-iPS-A, B, and C. (**), shared between 1018-iPS-A, B, and C. (#), cell lines
from Ma et al. (2014).
(B) Average number ± SEM of true heterozygous coding mutations in NT-ESCs, iPSCs, and pESCs. p value was determined by Mann-Whitney rank sum test.
NS, nonsignificant.
(C) An example of mutations where the mutated allele sequencing peak height is either the same height (TECTA) or less than 50%of the height (USP20) of the wild
type peak.
(D) Two examples of Sanger sequencing of dinucleotide mutations in NT-ESC and iPSC lines.
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an outlier control, we also analyzed parthenogenetic iPSCs (Pg-
iPSCs) (Stelzer et al., 2011), in which paternal imprints are
completely absent and aberrant expression of multiple imprinted
genes can be seen (Figure 3A). Both normal NT-ESCs and iPSCs
displayed some degree of variation in imprinted gene expres-
sion, which was higher than in ESCs, yet less extensive
compared with Pg-iPSCs (Figure 3A). Whereas SLC22A3
expression was only altered in a single NT-ESC line, the mater-
nally expressed genes H19 andMEG3 showed substantial upre-
gulation in a few NT-ESCs. Some iPSCs also showed variable
expression of a few imprinted genes, such as DLK1 and
NLRP2, in addition to moderate upregulation of H19 and
MEG3 (Figure 3A). This suggested that some loci may be subject
to loss of imprinting in NT-ESCs.
To address the possibility of local loss of imprinting, we exam-
ined allele-specific expression by direct cDNA sequencing. A
total of eight imprinted genes with confirmed heterozygous
SNPs, consisting of genes regulated by both maternally and
paternally inherited DNA methylation (four of each), and associ-
ated with five imprinted gene clusters across four different chro-
mosomes were analyzed (Figures 3B and S2A; summarized in
Table S4). Monoallelic expression of INPP5F (variant 2), NDN,
and IPW was observed across all cell lines tested (Figures 3B
and S2A). Consistent with gene expression data, IGF2was prop-
erly imprinted in all of the NT-ESC lines but showed biallelic
expression in one iPSC clone and contribution of a minor allele
in another iPSC clone (Figure 3B). H19, which was transcription-
ally upregulated in two of the NT-ESC clones, also showed loss
of imprinting in one of them (Figures 3A and 3B). The expression
levels ofMEG3 in NT-ESCs also correlated with its allele-specific
expression; biallelic expression or minor allele contribution were
detected only in those NT-ESC clones where MEG3 was tran-
scriptionally upregulated above 6.5-fold, and similar allelic pat-
terns were evident for the coregulated gene RTL1 (Figures 3A
and 3B). KCNQ1OT1 was the only gene with complete biallelic
expression in two of the NT-ESC clones (Figure 3B). Importantly,
none of the aberrations observed here could be attributed to the
parental fibroblast cell cultures (Figure 3B). Furthermore, direct
sequencing could be quantitatively reproduced for INPP5F,
H19, NDN, and IPW by analysis of nucleotide frequency from
RNA-Seq reads at corresponding polymorphic sites (Figures
3C and S2B).
To extend our allele-specific expression analysis, we analyzed
an isogenic pair of 1018-background-derived cell lines of
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Figure 3. Clone- and Gene-Specific Aberrations in Imprinted Gene Expression in Human NT-ESCs
(A) Heat map of 50 imprinted genes with detectable expression in human pluripotent stem cells. Shown are the microarray expression ratios of each sample
relative to the mean in the ESC samples (in logarithmic scale). The red and green color ranges denote at least 2-fold change.
(B) Sequencing of six representative imprinted genes in isogenic NT-ESCs, iPSCs, and their parental fibroblasts. Polymorphic sites in genomic DNA (gDNA),
indicated by arrows and a light blue background, were analyzed for allele-specific expression at the level of reverse-transcribed RNA (cDNA). Complete biallelic
expression is indicated by red asterisks and a light purple background. N/A, not available (summarized in Table S4).
(C) RNA-Seq-based quantification of allele-specific expression along the H19 transcript. Indicative polymorphic sites (reads n R 20) were analyzed by base
frequency (top panel) and allelic expression score (lower panel). Values between 0.4 and 0.6 (gray background) signify biallelic expression.
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NT-ESCs and iPSCs, where a subset of four imprinted genes
harbored indicative heterozygous SNPs. In both 1018-NT-
ESCs and iPSCs, INPP5F, H19, and IPWwere expressed mono-
allelically, whereas RTL1 showed biallelic expression in both
NT-ESCs and iPSCs (Figure S2C; Table S4). RTL1 was properly
imprinted in the parental fibroblast cell line, suggesting that loss
of imprinting occurred during reprogramming and independent
of the reprogramming method (Figure S3A).
Aberrant DNAHypomethylation in Imprinted Loci in Both
Human NT-ESCs and iPSCs
The epigenetic basis underlying genomic imprinting is parent-
of-origin-specific DNA methylation at imprinted differentially
methylated regions (iDMRs). To study DNA methylation in hu-
man NT-ESCs at a genome-wide scale, we utilized an array-
based platform comprising over 450,000 CpG sites distributed
throughout the human genome. The global DNA methylation
profiles of four NT-ESCs and eight isogenic iPSCs were highly
similar, with both cell types clearly distinguished from their
parental somatic cells, and clustering primarily by genetic
background (Figure 4A). Incorporation of additional samples
of human ESCs, NT-ESCs, iPSCs, and parental fibroblasts
into our clustering analysis showed that both the NT-ESC
group and iPSC group encompass individual cell lines that
vary in proximity to ESCs (Figure S3A). CpG sites associated
with classical pluripotency genes were consistently hypomethy-
lated in ESCs, iPSCs, and NT-ESCs compared with fibroblasts,
whereas fibroblast-specific genes were hypermethylated (Fig-
ure 4B, Table S5), demonstrating effective reprogramming by
either method.
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Figure 4. Global and Imprinting-Specific Patterns of DNA Methylation in Human NT-ESCs
(A) Hierarchical clustering analysis based on autosomal DNA methylation profiles of NT-ESCs, iPSCs, parental fibroblasts, and ESC line NYSCF1 (Pearson
correlation, average linkage).
(B) DNAmethylation levels at sites associated with pluripotency-specific genes and fibroblast-specific genes in ESCs, NT-ESCs, iPSCs, and parental fibroblasts
(Fibs). The blue and orange color ranges denote relative hypomethylation and hypermethylation, respectively (see Table S5).
(C) DNA methylation levels at known iDMRs in ESCs, NT-ESCs, and iPSCs. The blue and orange color ranges denote relative hypomethylation and hyper-
methylation, respectively (see Table S5).
(D) Box plots showing methylation levels at the H19, KvDMR1, and MEG3 DMRs in BJ-NT-ESCs compared with the mean levels in ESCs. The observed
monoallelic (M) or biallelic (B) expression of their corresponding imprinted genes is indicated. b values range from 0 to 1, indicating completely unmethylated and
completely methylated CpG sites, respectively. Values between 0.4 and 0.6 (gray background) signify intermediate methylation levels.
(E) Proportion of iDMRs with altered DNA methylation levels in human pluripotent stem cells from this study and from the study by Ma et al. (2014). (j Db j > 0.2,
where D is the difference from the mean levels in control ESCs; n = 6). p value was determined by two-tailed unpaired Student’s t test. NS, nonsignificant. Error
bars represent SEM. Related to Figure S3.
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We next examined DNAmethylation levels at CpG sites corre-
sponding to 35 known human iDMRs (Court et al., 2014) in
isogenic NT-ESC and iPSC lines compared with control ESCs,
as well as their parental fibroblasts.Whilemost iDMRs preserved
normal methylation levels in reprogrammed cells, variation in the
methylation status of several loci occurred in either or both
NT-ESCs and iPSCs, mostly due to hypomethylation (Figure 4C,
Table S5). For instance, hypomethylation of SNRPN- andGNAS-
associated DMRswas recurrent across samples, consistent with
previous reports in iPSCs (Nazor et al., 2012). Other loci,
including FAM50B, IGF2R, GRB10, and PEG3, showed clone-
specific alterations. Because the vast majority of loci were
intermediately and similarly methylated in both parental cell lines
(Figure S3B), the alterations observed in NT-ESCs and iPSCs
could not be attributed to their progenitor cells, with the excep-
tion of IGF1R DMR, which was hypomethylated in all 1018-
derived cells, as well as in their parental fibroblasts (average
b = 0.36, compared with 0.52 in BJ fibroblasts). Importantly,
both marked hypomethylation of the KvDMR1 DMR, which reg-
ulates paternal expression ofKCNQ1OT1, as well as more subtle
hypomethylation at the H19 and MEG3 DMRs, correlated with
biallelic expression of associated imprinted genes in NT-ESCs
(Figure 4D). Repeating this analysis on the published data sets
from Ma et al. (2014) also showed clone-specific alterations in
the methylation levels of multiple iDMRs in both NT-ESCs and
iPSCs (Figure S3). Notably, biallelic expression of H19 corre-
sponded with hypomethylation of the H19 DMR in some NT-
ESCs (Ma et al., 2014). Based on the data from this and the
aforementioned study, the DNA methylation status of around
10% of iDMRs is altered in both NT-ESCs and iPSCs, with statis-
tically nonsignificant differences between the two cell types (Fig-
ures 4E and S3D).
DISCUSSION
In this study, we compared aspects of genetic and epigenetic
stability of human pluripotent stem cells reprogrammed by either
nuclear transfer or defined factors. Using the same somatic cell
cultures to generate isogenic NT-ESCs and iPSCs, we found no
difference in the average number of somatic coding mutations.
Therefore, the occurrence of de novo coding mutations is
inherent to somatic cell reprogramming. On average, 12.5% of
all confirmed mutations were shared between more than one
cell line, suggesting that a considerable number of coding
mutations identified in reprogrammed stem cells preexisted in
somatic cell cultures, a conclusion that is in line with previous
reports (Gore et al., 2011; Ji et al., 2012; Young et al., 2012).
Fetal, neonatal, and adult cell lines all contained a similar number
of unique coding mutations, while more mutations were shared
between cell lines of adult origin. Contrary to this study, a study
in mice suggested that mutagenic stresses during reprogram-
ming might be method specific, reporting 0–9 (average of 2.8)
unique coding mutations in NT-ESCs compared to 3–12
(average of 9.8) in iPSCs generated from syngenic mouse em-
bryonic fibroblasts (Li et al., 2014). Li et al.’s use of mouse
embryonic fibroblasts, which may harbor a lower number of
preexisting mutations than cultured human somatic cells, could
in principle have enhanced their ability to detect method-
specific differences. However, as opposed to this study, Li and
colleagues did not use the same batch of fibroblasts for different
reprogramming experiments, limiting their ability to compare
mutation rates between the two methods.
We also show that NT-ESCs derived from independent
somatic cell lines variably acquire clone- and gene-specific
aberrations in DNA methylation and allele-specific expression
of imprinted genes, similarly to iPSCs (Nazor et al., 2012; Nishino
et al., 2011; Pick et al., 2009). Importantly, relaxation of
imprinting of a certain gene does not predict the imprinting status
of other loci in the same clone, and specific genes appear to
differ in their perturbation frequency across cell lines, arguing
in favor of stochastic loss of imprinting. In support of these find-
ings, analysis of data from the study by Ma et al. revealed a
similar stochastic incidence of imprinting abnormalities in human
NT-ESCs and iPSCs, including aberrant DNA methylation and
biallelic expression of several imprinted genes in NT-ESCs.
Low levels of imprinting aberrations could, in principle, preexist
in the parental somatic cells and be clonally expanded during re-
programming, or alternatively, they could occur during reprog-
ramming. The fairly stable status of imprinting in human ESCs
(Adewumi et al., 2007; Rugg-Gunn et al., 2007) allowed us to
conclude that imprinting aberrations in reprogrammed cells are
the consequence of their somatic origin and occur indepen-
dently of the reprogramming method. Intriguingly, some of the
aberrations we observed in NT-ESCs are very rare in ESCs, likely
reflecting fundamental differences between SCNT and normal
fertilization.
Contrary to direct factor-mediated reprogramming, which in-
volves predetermined genetic manipulation, the acquisition of
pluripotency through SCNT is leveraged by events that run par-
allel to preimplantation development. This inherent distinction
could, in principle, give rise to differences between the resulting
reprogrammed pluripotent stem cells. Nevertheless, with re-
gards to de novo coding mutations and stability of imprinted
gene regulation, we show that both reprogramming techniques
lead to a comparable incidence of these perturbations in human
NT-ESCs and iPSCs. While the genetic and epigenetic aberra-
tions described here following SCNT disqualify its use for
reproductive purposes, NT-ESCs, as well as iPSCs, will require
appropriate quality controls prior to their use in a therapeutic
context. Both NT-ESCs and iPSCs closely resemble one another
judging by their global transcriptional and DNA methylation sig-
natures. In contrast to a previous study with fetal fibroblast-
derived stem cell lines (Ma et al., 2014), we have not observed
distinct clustering of BJ- and 1018-derived NT-ESCs and iPSCs.
Differences between the two studies are not due to methods of
analysis, because we were able to reproduce the distinct clus-
tering of fetal-fibroblast-derived iPSCs and NT-ESCs (Fig-
ure S3A). Possible differences may be related to the techniques
used for iPSC generation; we used transient RNA transfections
as opposed to retroviral vectors or Sendai virus, whose ex-
pression may be retained in iPSCs (Fusaki et al., 2009). Further-
more, while Ma and colleagues focused on fetal cells, the
present study also included cell lines of adult and neonatal origin,
enhancing its ability to capture the heterogeneity inherent to
pluripotent stem cells (Bock et al., 2011). Though our study pro-
vides evidence that the two reprogramming methods result in
highly similar cell types, we believe it cannot be taken as proof
for equivalence between iPSCs andNT-ESCs. Additional studies
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of differentiation capacity and possible retention of somatic cell
features using a larger number of NT-ESC lineswill be required to
resolve this question.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
The derivation of human fibroblasts, soPSCs, pESCs, diploid and triploid NT-
ESCs, and virally reprogrammed iPSCs was described before (Noggle et al.,
2011; Paull et al., 2013; Maehr et al., 2009; Ma et al., 2014; Tachibana et al.,
2013). Tetraploid NT-ESCs were generated by artificial activation in the pres-
ence of cytochalasin B, and isogenic iPSCswere generated using RNA reprog-
ramming (Stemgent). Somatic cell donors for soPSCs and isogenic iPSCs
were a 30-year-old male subject affected by type 1 diabetes (ID 1-000) or a
34-year-old healthy male (ID-1016).
Coding Mutations Analysis
Whole-exome sequencing was performed using Illumina HiSeq 2500.
Sequencing data was analyzed as previously described (Gore et al., 2011)
and candidate mutations were verified by Sanger sequencing.
Gene Expression Analyses
RNA-Seq was performed using Illumina HiSeq 2500, reads were aligned to the
human genome (NCBI/build37.2) using Tophat (version 2.0.4), and FPKM
values were calculated using Cufflinks (version 2.0.2). Expression microarray
data sets included in this study were obtained using Affymetrix Human Gene
1.0 ST. For allele-specific gene expression analyses, we used Sanger
sequencing and RNA-Seq data based on confirmed heterozygous SNPs.
Array-Based DNA Methylation Analysis
DNA methylation analysis was performed using Illumina’s Infinium
HumanMethylation450 BeadChips. Analysis was carried out using
GenomeStudio (Illumina) and the R package ChAMP (version 1.2.7).
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